AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21803569 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10mg once daily
Number of subjects: 1367
Study 21804667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse transit time (PTT) monitoring during nocturnal study
Number of subjects: 780
Study 21805584 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) with modern versions of the Carotid Wallstent and FilterWire EZ System
Number of subjects: 1097
Study 21805607 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen Biomedical FiberNet® embolic protection system
Number of subjects: 20
Study 21807867 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin <14 pmol/L plus hscTnT <14 ng/L
Number of subjects: 503
Study 21807867 — intervention group
Group type: COMPARATOR
Intervention: hscTnT alone
Number of subjects: 503
Study 21808855 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth breathing group
Number of subjects: 55
Study 21808855 — intervention group
Group type: COMPARATOR
Intervention: Nasal breathing group
Number of subjects: 55
Study 21809989 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical teratoid/rhabdoid tumors (AT/RTs)
Number of subjects: 96
Study 21809989 — intervention group
Group type: COMPARATOR
Intervention: Medulloblastomas (MBs)
Number of subjects: 96
Study 21811626 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC)
Number of subjects: 1001
Study 21811626 — intervention group
Group type: COMPARATOR
Intervention: Central venous catheter (CVC)
Number of subjects: 1001
Study 21812019 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide
Number of subjects: 32
Study 21812576 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) levels on admission
Number of subjects: 40
Study 21812736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg once daily for 12 weeks
Number of subjects: 25
Study 21812736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 10 mg once daily for an additional 12 weeks
Number of subjects: 25
Study 21812736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg and 10 mg
Number of subjects: 25
Study 21812775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumavel DosePro (needle-free subcutaneous sumatriptan) 6 mg
Number of subjects: 212
Study 21812908 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 14
Study 21812991 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT) with therapist support for 15 weeks
Number of subjects: 23
Study 21812991 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT) with therapist support
Number of subjects: 23
Study 21813383 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green plasma disappearance rate (ICG-PDR)
Number of subjects: 86
Study 21813383 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green plasma disappearance rate (ICG-PDR) on day 7
Number of subjects: 86
Study 21814460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (5 or 10 μg) via Respimat® Soft Mist™ Inhaler
Number of subjects: 1990
Study 21814460 — intervention group
Group type: COMPARATOR
Intervention: Placebo via Respimat® Soft Mist™ Inhaler
Number of subjects: 1990
Study 21815133 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg on days 1 and 15 and topotecan 4 mg/m² on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 40
Study 21815133 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity assessment
Number of subjects: 40
Study 21815182 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of decitabine, arsenic trioxide, and ascorbic acid
Number of subjects: 0
Study 21815705 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin lactone to atorvastatin acid ratio with a cut-off ratio set at 1.1
Number of subjects: 53
Study 21816031 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS, S malaria candidate vaccine
Number of subjects: 0
Study 21816031 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized assessment program for severe malaria
Number of subjects: 0
Study 21816032 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria candidate vaccine
Number of subjects: 0
Study 21816032 — intervention group
Group type: COMPARATOR
Intervention: Standardized laboratory methods and quality assurance processes
Number of subjects: 0
Study 21816305 — intervention group
Group type: EXPERIMENTAL
Intervention: Single PCI strategy
Number of subjects: 668
Study 21816305 — intervention group
Group type: COMPARATOR
Intervention: Staged PCI strategy
Number of subjects: 668
Study 21816308 — intervention group
Group type: EXPERIMENTAL
Intervention: Early repolarization in patients with idiopathic ventricular fibrillation (IVF)
Number of subjects: 100
Study 21816308 — intervention group
Group type: COMPARATOR
Intervention: Established cause of cardiac arrest
Number of subjects: 100
Study 21816308 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial ECGs
Number of subjects: 100
Study 21816436 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI colon cancer cells (HCT116)
Number of subjects: 0
Study 21816436 — intervention group
Group type: COMPARATOR
Intervention: MSS colon cancer cells (HT29)
Number of subjects: 0
Study 21816436 — intervention group
Group type: COMPARATOR
Intervention: Normal colonic mucosa (NCM)
Number of subjects: 0
Study 21816790 — intervention group
Group type: EXPERIMENTAL
Intervention: Amenorrheic athletes (AA)
Number of subjects: 50
Study 21816790 — intervention group
Group type: EXPERIMENTAL
Intervention: Eumenorrheic athletes (EA)
Number of subjects: 50
Study 21816790 — intervention group
Group type: COMPARATOR
Intervention: Nonathletic controls
Number of subjects: 50
Study 21816790 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing tibia
Number of subjects: 50
Study 21816790 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject grouping
Number of subjects: 50
Study 21816832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative HSCT with matched-related donors
Number of subjects: 6
Study 21816832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative HSCT with matched-unrelated donors
Number of subjects: 6
Study 21816832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative HSCT with umbilical cord blood donors
Number of subjects: 6
Study 21816832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative HSCT
Number of subjects: 6
Study 21816832 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 6
Study 21816833 — intervention group
Group type: EXPERIMENTAL
Intervention: New inhibitors of BCR signaling
Number of subjects: 0
Study 21816833 — intervention group
Group type: EXPERIMENTAL
Intervention: BCR signaling blockade
Number of subjects: 0
Study 21816912 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cortisol
Number of subjects: 57
Study 21816912 — intervention group
Group type: EXPERIMENTAL
Intervention: Free serum cortisol
Number of subjects: 57
Study 21816912 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum cortisol
Number of subjects: 57
Study 21816912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol-binding globulin (CBG)
Number of subjects: 57
Study 21818149 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects
Number of subjects: 72
Study 21818149 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 72
Study 21818676 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT), 80 sessions
Number of subjects: 10
Study 21818676 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 10
Study 21819438 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced GH secretion (n = 35)
Number of subjects: 102
Study 21819438 — intervention group
Group type: COMPARATOR
Intervention: Sufficient GH secretion (n = 34)
Number of subjects: 102
Study 21819438 — intervention group
Group type: COMPARATOR
Intervention: Normal weight subjects (n = 33)
Number of subjects: 102
Study 21819507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal EPO injection (1000 IU/0.05 mL)
Number of subjects: 11
Study 21819507 — intervention group
Group type: COMPARATOR
Intervention: Control group (cataract surgery patients, 10 eyes of 10 patients)
Number of subjects: 11
Study 21820136 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting energy expenditure (REE)
Number of subjects: 108
Study 21820279 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic atrial fibrillation (AF) management in the ED
Number of subjects: 430
Study 21821014 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell distribution width (RDW) in patients with CAD
Number of subjects: 1489
Study 21821014 — intervention group
Group type: COMPARATOR
Intervention: Red cell distribution width (RDW) in normal (No-CAD) patients
Number of subjects: 1489
Study 21821014 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP) in patients with CAD
Number of subjects: 1489
Study 21821340 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and lifestyle interventions
Number of subjects: 11991
Study 21821340 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based health interview and examination survey
Number of subjects: 11991
Study 21821340 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year prospective follow-up
Number of subjects: 11991
Study 21821712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 5.6 mg/m² IV over 2 hours daily for 5 days followed by rituximab 375 mg/m² IV weekly for 8 weeks
Number of subjects: 36
Study 21823120 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus chemotherapy
Number of subjects: 25
Study 21823120 — intervention group
Group type: COMPARATOR
Intervention: Nodal DLBCL (control group)
Number of subjects: 25
Study 21823120 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary breast DLBCL
Number of subjects: 25
Study 21823912 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (APZ) at flexible doses (maximum 15 mg/day) for up to 16 weeks
Number of subjects: 96
Study 21823912 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (APZ)
Number of subjects: 96
Study 21824425 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnT elevation screening and coronary angiography within 72 hours
Number of subjects: 0
Study 21824425 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnT elevation screening
Number of subjects: 0
Study 21824425 — intervention group
Group type: COMPARATOR
Intervention: Non-ST-Elevation myocardial infarction
Number of subjects: 0
Study 21824458 — intervention group
Group type: EXPERIMENTAL
Intervention: Short half-life antidepressants
Number of subjects: 21
Study 21824458 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 21
Study 21824458 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant exposure
Number of subjects: 21
Study 21824458 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall antidepressant exposure
Number of subjects: 21
Study 21824941 — intervention group
Group type: EXPERIMENTAL
Intervention: Home delivery of radiology services
Number of subjects: 0
Study 21824941 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard radiology services)
Number of subjects: 0
Study 21826527 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (60 mg/m²) on Day 1, vinorelbine (27.5 mg/m²) on Days 8 and 15, filgrastim (5 µg/kg) on Days 2-21, and weekly trastuzumab (2 mg/kg after an initial bolus of 4 mg/kg)
Number of subjects: 74
Study 21826527 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel, vinorelbine, filgrastim, and trastuzumab
Number of subjects: 74
Study 21827541 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cardiovascular risk factors (diabetes, hypertension, obesity, dyslipidemia, smoking, family history)
Number of subjects: 246
Study 21827541 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cardiovascular risk factors
Number of subjects: 246
Study 21827541 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index, diastolic blood pressure, age, and fasting plasma glucose
Number of subjects: 246
Study 21828124 — intervention group
Group type: EXPERIMENTAL
Intervention: High VLA-4 expression
Number of subjects: 56
Study 21828124 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking of VLA-4 signaling in combination with cytarabine treatment
Number of subjects: 56
Study 21828134 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Number of subjects: 39
Study 21828141 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m², four weekly applications)
Number of subjects: 28
Study 21828142 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 15
Study 21828142 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 15
Study 21828142 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PDGFRA antibodies
Number of subjects: 15
Study 21828157 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 135
Study 21828157 — intervention group
Group type: COMPARATOR
Intervention: Baseline ChBF
Number of subjects: 135
Study 21828157 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure response to isometric exercise
Number of subjects: 135
Study 21828157 — intervention group
Group type: COMPARATOR
Intervention: Baseline arterial blood pressure
Number of subjects: 135
Study 21829612 — intervention group
Group type: COMPARATOR
Intervention: riluzole
Number of subjects: 760
Study 21829612 — intervention group
Group type: EXPERIMENTAL
Intervention: NNIPPS-PPS scale
Number of subjects: 760
Study 21829931 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Length Utterance for words (MLU-w)
Number of subjects: 15
Study 21829931 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Length Utterance for morphemes (MLU-m)
Number of subjects: 15
Study 21829931 — intervention group
Group type: EXPERIMENTAL
Intervention: Grammatical morphemes (GM) for articles, nouns and verbs (GM-1)
Number of subjects: 15
Study 21829931 — intervention group
Group type: EXPERIMENTAL
Intervention: Grammatical morphemes (GM) for pronouns, prepositions and conjunctions (GM-2)
Number of subjects: 15
Study 21831297 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine patch (dosage ratio of 1.5:1)
Number of subjects: 116
Study 21831297 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine patch
Number of subjects: 116
Study 21831297 — intervention group
Group type: COMPARATOR
Intervention: Oral ropinirole
Number of subjects: 116
Study 21831304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleurotus ostreatus (15 gm/day) for 8 weeks
Number of subjects: 20
Study 21831685 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole therapy
Number of subjects: 25
Study 21831743 — intervention group
Group type: EXPERIMENTAL
Intervention: autoSCT
Number of subjects: 68
Study 21831743 — intervention group
Group type: EXPERIMENTAL
Intervention: alloSCT
Number of subjects: 68
Study 21831743 — intervention group
Group type: EXPERIMENTAL
Intervention: RICE
Number of subjects: 68
Study 21831743 — intervention group
Group type: EXPERIMENTAL
Intervention: FluBu
Number of subjects: 68
Study 21831743 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 68
Study 21831954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg QD
Number of subjects: 28
Study 21831954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg QD
Number of subjects: 28
Study 21831954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (200-800 mg)
Number of subjects: 28
Study 21831954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 28
Study 21832276 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 80
Study 21833452 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IL-11 (rhIL-11, Neumega®) given subcutaneously for up to seven days during six consecutive menstrual cycles
Number of subjects: 7
Study 21833452 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IL-11 (rhIL-11, Neumega®)
Number of subjects: 7
Study 21835005 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated red cell distribution width (RDW) > 14.5%
Number of subjects: 637
Study 21835005 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 51 years, prior neurologic damage, immunosuppression, combination of abnormal white blood cells (WBC) and elevated RDW
Number of subjects: 637
Study 21835005 — intervention group
Group type: EXPERIMENTAL
Intervention: Post chest radiation state, prior neurologic damage, blood urea nitrogen (BUN) > 10.7 mmol/L, RDW > 14.5%
Number of subjects: 637
Study 21835005 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased RDW regardless of white blood cell count
Number of subjects: 637
Study 21835005 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated RDW
Number of subjects: 637
Study 21835825 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA404 (1800 mg/m²) plus docetaxel (75 mg/m²)
Number of subjects: 9
Study 21835825 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA404 (1800 mg/m²) plus docetaxel (60 mg/m²)
Number of subjects: 9
Study 21836106 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual short sleep (average of 1.5 h less sleep per night)
Number of subjects: 47
Study 21836106 — intervention group
Group type: COMPARATOR
Intervention: Usual sleep duration >6 h/day
Number of subjects: 47
Study 21836107 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessment in youth with type 2 diabetes
Number of subjects: 704
Study 21836107 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of depressive symptoms in older girls vs older boys
Number of subjects: 704
Study 21836107 — intervention group
Group type: COMPARATOR
Intervention: Comparison of depressive symptoms in youth with type 2 diabetes vs healthy adolescents
Number of subjects: 704
Study 21836107 — intervention group
Group type: COMPARATOR
Intervention: Comparison of depressive symptoms in youth with type 2 diabetes vs teens with type 1 diabetes
Number of subjects: 704
Study 21836143 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine IL-18
Number of subjects: 1219
Study 21836143 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL
Number of subjects: 1219
Study 21836143 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine NGAL
Number of subjects: 1219
Study 21836143 — intervention group
Group type: COMPARATOR
Intervention: Clinical prediction model for AKI
Number of subjects: 1219
Study 21836143 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine IL-18 and Plasma NGAL
Number of subjects: 1219
Study 21836147 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine IL-18
Number of subjects: 311
Study 21836147 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine NGAL
Number of subjects: 311
Study 21836147 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine IL-18 and Urine NGAL
Number of subjects: 311
Study 21836147 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL
Number of subjects: 311
Study 21838412 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg orally once daily for days 1 to 3; 0.5 mg twice daily for days 4 to 7; 1 mg twice daily for the remainder of a 12-week treatment period)
Number of subjects: 330
Study 21838412 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 330
Study 21838881 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma osteoprotegerin (OPG) levels in patients with carotid arterial disease
Number of subjects: 305
Study 21838881 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma osteoprotegerin (OPG) levels in patients with peripheral arterial disease
Number of subjects: 305
Study 21838881 — intervention group
Group type: COMPARATOR
Intervention: Myocardial ischemia
Number of subjects: 305
Study 21839411 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference-based measure derived from EORTC QLQ-C30
Number of subjects: 655
Study 21839411 — intervention group
Group type: EXPERIMENTAL
Intervention: Valuation study using time trade-off
Number of subjects: 655
Study 21839981 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1487
Study 21839981 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1487
Study 21839981 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI quintiles
Number of subjects: 1487
Study 21839981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex (Women)
Number of subjects: 1487
Study 21839981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex by BMI interaction
Number of subjects: 1487
Study 21840522 — intervention group
Group type: EXPERIMENTAL
Intervention: NRS 4-6
Number of subjects: 10434
Study 21840522 — intervention group
Group type: COMPARATOR
Intervention: NRS scores interpretation by professionals
Number of subjects: 10434
Study 21840522 — intervention group
Group type: COMPARATOR
Intervention: NRS scores interpretation by Acute Pain Nurses
Number of subjects: 10434
Study 21840522 — intervention group
Group type: COMPARATOR
Intervention: Guidelines for analgesic treatment
Number of subjects: 10434
Study 21840837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilyze! intervention
Number of subjects: 8
Study 21841163 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine combined with myeloablative doses of busulfan
Number of subjects: 46
Study 21844482 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation
Number of subjects: 10
Study 21845241 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen barrier membrane
Number of subjects: 10
Study 21846339 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe Hepatic Steatosis (HS)
Number of subjects: 48
Study 21846339 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I zSDS
Number of subjects: 48
Study 21846339 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-1
Number of subjects: 48
Study 21846339 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I/IGFBP-3 ratio
Number of subjects: 48
Study 21846339 — intervention group
Group type: EXPERIMENTAL
Intervention: FM%
Number of subjects: 48
Study 21846339 — intervention group
Group type: EXPERIMENTAL
Intervention: SLD
Number of subjects: 48
Study 21846371 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d reduced viscosity barley β-glucan (BBG)
Number of subjects: 50
Study 21846371 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/d reduced viscosity barley β-glucan (BBG)
Number of subjects: 50